International Ketamine Research: Global Developments and Discoveries

The Global Research Landscape

While much of the conversation about ketamine therapy centers on the United States, ketamine research is a thoroughly international endeavor. Researchers and clinicians across Europe, Asia, Australia, Canada, and Latin America are conducting important work that is shaping the global understanding of how ketamine works, who it can help, and how it should be administered.

The international research landscape offers several advantages. Different regulatory environments allow for study designs that may be more difficult to conduct in the US. Cultural and healthcare system differences provide natural variations that can reveal how context affects treatment outcomes. And the sheer diversity of research programs increases the likelihood of novel discoveries and approaches.

This article surveys the most significant international ketamine research developments, organized by region.

Europe

United Kingdom

The UK has emerged as one of the most active centers for ketamine research outside the United States. Several developments are particularly noteworthy:

Ketamine vs. ECT Trials — British researchers have been at the forefront of head-to-head comparisons between ketamine and electroconvulsive therapy (ECT). These trials are critically important because ECT is currently considered the most effective treatment for severe, treatment-resistant depression, but it carries significant side effects including memory loss and requires general anesthesia. Early results from UK-based trials suggest that ketamine may offer comparable efficacy to ECT for some patient populations with a more favorable side effect profile. The multi-site Ketamine vs ECT for Depression (KetECT) study, coordinated through the UK's National Health Service research infrastructure, has been generating data that could shift clinical practice guidelines internationally.

NHS Ketamine Services — The UK's National Health Service has been cautiously expanding access to ketamine therapy at select mental health trusts. Several NHS hospitals now offer ketamine infusions for treatment-resistant depression within a structured clinical framework, providing a model for how publicly funded healthcare systems can integrate ketamine into routine psychiatric care. The NHS model emphasizes careful patient selection, standardized protocols, and outcome monitoring — data from which is contributing to the international evidence base.

Oxford and Cambridge Research Programs — The universities of Oxford and Cambridge have active ketamine research programs investigating mechanisms of action, biomarkers of response, and novel treatment protocols. Oxford researchers have published influential work on the neuroimaging correlates of ketamine response, using functional MRI to identify brain connectivity patterns that predict who will benefit from treatment.

Germany and Central Europe

German researchers have contributed significantly to the understanding of ketamine's mechanisms of action:

• Glutamate system research — German neuroscience labs have produced important basic science work on how ketamine modulates glutamate signaling, particularly through its effects on AMPA receptors and downstream signaling cascades involving BDNF and mTOR
• Ketamine in emergency psychiatry — German emergency departments have been among the first in Europe to study and implement ketamine protocols for acute suicidal crises, generating data on the feasibility and effectiveness of this approach in real-world emergency settings
• Pain research networks — Central European pain research networks have conducted multi-site studies of ketamine for various chronic pain conditions, contributing to the evidence base for pain-related applications

The Netherlands

The Netherlands has a notable history of progressive approaches to psychoactive substance research, and ketamine is no exception:

• Ketamine and addiction — Dutch researchers have conducted several important studies on ketamine's potential for treating alcohol use disorder, including work on how ketamine may disrupt maladaptive reward memories associated with addiction
• Pharmacokinetic studies — Detailed pharmacokinetic and pharmacodynamic modeling from Dutch research groups has helped clarify how ketamine and its metabolites behave in the body, informing dosing optimization worldwide

Scandinavian Countries

Nordic countries have contributed methodologically rigorous research leveraging their comprehensive healthcare registries:

• Registry-based outcome studies — Scandinavian researchers have used national patient registries to conduct large-scale observational studies of ketamine treatment outcomes, providing real-world effectiveness data that complements smaller clinical trials
• Ketamine in palliative care — Swedish and Norwegian research groups have investigated ketamine's role in palliative care settings, both for pain management and for existential distress in patients with terminal illness

Asia-Pacific

Japan

Japan is at the center of one of the most significant developments in the ketamine field: the clinical development of arketamine (R-ketamine).

Arketamine (R-Ketamine) Trials — Japanese pharmaceutical company Perception Neuroscience (in collaboration with academic researchers) has been advancing arketamine through clinical trials. Arketamine is the R-enantiomer of ketamine, distinct from the S-enantiomer (esketamine) that is marketed as Spravato. Preclinical research, much of it originating in Japanese laboratories, suggests that arketamine may have antidepressant effects comparable to or exceeding those of esketamine, with significantly fewer dissociative side effects. Japanese Phase 2 trials have reported encouraging results, and the compound is being advanced toward larger-scale testing. If arketamine proves effective and tolerable in Phase 3 trials, it could represent a transformative advance in the field.

Mechanistic Research — Japanese neuroscience labs, particularly those led by Professor Kenji Hashimoto at Chiba University, have been instrumental in elucidating the mechanisms by which R-ketamine differs from S-ketamine. This work has challenged the assumption that NMDA receptor blockade is the primary mechanism underlying ketamine's antidepressant effects, instead pointing to alternative pathways involving AMPA receptors, BDNF-TrkB signaling, and gut microbiome modulation.

China

Chinese researchers have made substantial contributions across multiple areas of ketamine research:

• Large-scale clinical studies — China's large patient population and growing research infrastructure have enabled clinical studies of ketamine with sample sizes that are difficult to achieve elsewhere. Chinese studies of ketamine for depression, chronic pain, and perioperative applications have contributed important data to systematic reviews and meta-analyses
• Pain research — Chinese universities and hospitals have conducted extensive research on ketamine for various pain conditions, including postoperative pain, cancer pain, and neuropathic pain. Studies from Chinese institutions have been particularly influential in establishing optimal ketamine dosing for pain management
• Ketamine and inflammation — Chinese research groups have investigated the anti-inflammatory properties of ketamine, exploring how its effects on inflammatory markers such as IL-6 and TNF-alpha may contribute to both its antidepressant and analgesic effects
• Combination studies — Researchers in China have conducted studies combining ketamine with other treatments (including traditional Chinese medicine approaches), providing data on drug interactions and combination efficacy

Australia

Australia has developed a distinctive approach to ketamine research and clinical practice:

Innovative Clinic Models — Australian ketamine clinics have developed treatment protocols that integrate elements of psychotherapy with ketamine administration more systematically than is typical in many US clinics. These models, which blend pharmacological treatment with structured therapeutic support, are generating clinical outcome data that informs the ketamine-assisted psychotherapy field internationally.

Oral Ketamine Research — Australian researchers have conducted some of the most important studies on oral and sublingual ketamine for depression, including dose-finding studies and comparisons of different oral formulations. This work is particularly relevant given the growing interest in oral ketamine as a more accessible and affordable alternative to IV infusion.

Rural and Remote Access — Australia's vast geography and rural populations have driven research into telehealth-supported ketamine treatment models, where patients in remote areas receive ketamine under local medical supervision with remote psychiatric oversight. This model has implications for improving access in rural areas worldwide.

South Korea and Taiwan

Researchers in South Korea and Taiwan have contributed to the ketamine literature through:

• Neuroimaging studies examining ketamine's effects on brain structure and function
• Genetic and pharmacogenomic studies in East Asian populations, which may have different metabolic profiles than Western populations
• Clinical studies of ketamine in perioperative and emergency medicine settings

Canada

Canadian researchers and clinicians have been active contributors to the ketamine field:

Canadian Network for Mood and Anxiety Treatments (CANMAT) — CANMAT has published clinical guidelines that include ketamine and esketamine recommendations for treatment-resistant depression, providing an influential framework that is referenced internationally. These guidelines represent one of the most comprehensive professional society positions on ketamine therapy.

Health Canada Regulatory Framework — Canada's regulatory approach to ketamine therapy has evolved to permit its clinical use for treatment-resistant depression through the Special Access Programme and, more recently, through direct clinical prescribing. The Canadian experience provides a regulatory model that differs from the US approach and offers lessons for other countries.

Academic Research Programs — Major Canadian universities, including the University of British Columbia, University of Toronto, and McGill University, have active ketamine research programs covering basic science, clinical trials, and health services research. Canadian researchers have made notable contributions to understanding ketamine's effects on neuroplasticity and the glutamate system.

Indigenous Health Applications — Some Canadian researchers have begun exploring the potential role of ketamine therapy in addressing the mental health crisis in Indigenous communities, where rates of depression, PTSD, and suicidality are disproportionately high. This work is conducted in collaboration with Indigenous communities and health authorities.

Latin America

Brazil

Brazil has been an important contributor to ketamine research, with several pioneering studies:

• Early clinical work — Brazilian researchers were among the first to publish clinical data on ketamine for depression outside of the United States, with early case series and open-label studies that helped build the international evidence base
• Ketamine for suicidal ideation — Brazilian emergency psychiatry researchers have conducted studies of ketamine for acute suicidal ideation in emergency department settings, contributing to understanding of ketamine's rapid anti-suicidal effects
• Low-resource settings — Research from Brazil has explored how ketamine therapy can be implemented in lower-resource healthcare settings, which is relevant for many countries worldwide where the high cost of specialized infusion clinics is prohibitive

Mexico and Argentina

Emerging research programs in Mexico and Argentina have focused on:

• Ketamine for treatment-resistant depression in public hospital systems
• Pain management applications, particularly for chronic pain conditions with limited treatment options
• Adapting treatment protocols to local healthcare infrastructure and patient populations

Regulatory Trends Internationally

Ketamine's regulatory status varies considerably across countries, and several trends are noteworthy:

• Controlled substance classification — Most countries classify ketamine as a controlled or restricted substance, but the specific schedule and restrictions differ. Some countries are more restrictive than the US, while others permit broader clinical use
• Off-label prescribing — The degree to which physicians can prescribe ketamine off-label varies internationally. Some countries have relatively permissive off-label prescribing frameworks, while others require special authorization
• Esketamine approval — Following FDA approval of Spravato in the US, regulatory agencies in Europe (EMA), Canada, Australia, Japan, and other countries have approved or are reviewing esketamine, though specific indications and access programs differ
• Clinical practice guidelines — International professional societies are increasingly issuing guidelines that include ketamine and esketamine, though recommendations vary in their specificity and strength

How International Research Affects US Practice

International ketamine research influences US practice in several important ways:

• Expanding the evidence base — Studies from other countries are included in systematic reviews and meta-analyses that guide US clinical practice guidelines
• Novel protocols — Treatment protocols developed internationally (such as Australian oral ketamine protocols and UK ketamine-ECT comparison data) inform US clinical innovation
• Regulatory precedent — International regulatory decisions can influence FDA and state-level policy, particularly when other developed nations adopt more permissive approaches
• Drug development — Compounds originating in international research programs (such as arketamine from Japanese research) may eventually become available in the US market

Key Researchers and Institutions

Several international researchers and institutions have been particularly influential in advancing the ketamine field:

• Professor Kenji Hashimoto, Chiba University, Japan — Pioneering work on R-ketamine mechanisms and arketamine development
• Professor Rupert McShane, University of Oxford, UK — Leading UK-based clinical trials comparing ketamine to ECT and developing NHS ketamine services
• CANMAT (Canadian Network for Mood and Anxiety Treatments) — Influential clinical guidelines incorporating ketamine
• Professor Colleen Loo, University of New South Wales, Australia — Leading Australian clinical research on ketamine for depression, including oral formulation studies
• Professor Carlos Zarate Jr., though US-based at NIMH, collaborates extensively with international teams, and many international programs were inspired by his foundational work

The international scope of ketamine research ensures that no single country or research tradition has a monopoly on discovery. As data from diverse populations, healthcare systems, and regulatory environments continues to accumulate, the global ketamine research community is building an increasingly complete picture of how this treatment can best serve patients worldwide. For US-specific developments, see our 2025 research roundup and the IV infusion protocols resource.

References

• Ketamine's Mechanism of Action: A Path to Rapid-Acting Antidepressants — NIH review of the scientific foundations underlying international ketamine research
• WHO: Depression — World Health Organization fact sheet on global depression burden and treatment approaches
• StatPearls: Ketamine — Clinical reference covering ketamine's role as a WHO Essential Medicine and its global clinical applications
• Ketamine: NMDA Receptors and Beyond — NIH article on emerging mechanisms of ketamine action relevant to international research programs